Holen Sie sich die Stockscreener-App
0.4909
9.82%
0.0439
Handel nachbörslich:
.51
0.0191
+3.89%
Schlusskurs vom Vortag:
$0.447
Offen:
$0.459
24-Stunden-Volumen:
2.75M
Relative Volume:
0.77
Marktkapitalisierung:
$19.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.04M
KGV:
-0.2486
EPS:
-1.9743
Netto-Cashflow:
$-17.53M
1W Leistung:
+20.73%
1M Leistung:
+26.75%
6M Leistung:
-80.52%
1J Leistung:
-86.44%
1-Tages-Spanne:
$0.4578
$0.5153
1-Wochen-Bereich:
$0.3912
$0.5153
52-Wochen-Spanne:
$0.37
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Firmenname
Medicus Pharma Ltd
Sektor
Telefon
610-540-7515
Adresse
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.4909 | 17.59M | 0 | -27.04M | -17.53M | -1.9743 |
LLY
Lilly Eli Co
|
927.06 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.97 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.69 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
202.83 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.85 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten
Medicus Pharma submits optimized Phase 2 study design for Teverelix - Proactive financial news
Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... - Proactive financial news
Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market - TipRanks
Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA - Yahoo Finance
Medicus targets recurrent urinary retention with 126-patient study - Stock Titan
EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate - Benzinga
Medicus Pharma submits optimized Phase 2 protocol for Teverelix - grafa.com
Medicus Pharma SkinJect Phase 2 study data endorsed by independent expertICYMI - Proactive financial news
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - gosanangelo.com
Medicus Pharma stock swings after skin cancer treatment results - MSN
Medicus Pharma on Bloomberg World - Bluffton Today
Medicus Pharma Ltd. (MDCX) stock price, news, quote and history - Yahoo Finance Singapore
Medicus Pharma clarifies Phase 2 skin cancer study results By Investing.com - Investing.com South Africa
MDCX SEC FilingsMedicus Pharma Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
MDCX Forecast, Price Target & Analyst Ratings | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma (MDCX) COO granted 50,000 options at $0.50 exercise price - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) awarded 25,000 stock options at $0.50 - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) receives 25,000 stock options at $0.50 strike - Stock Titan
CMO at Medicus Pharma (MDCX) receives 125,000 stock options grant - Stock Titan
[Form 4] Medicus Pharma Ltd. Insider Trading Activity - Stock Titan
Medicus Pharma (MDCX) director granted stock options for 25,000 Common Shares - Stock Titan
Director Barry Fishman granted 25,000 Medicus Pharma (MDCX) stock options - Stock Titan
Medicus Pharma (MDCX) grants director 25K stock options at $0.50 - Stock Titan
Medicus Pharma (MDCX) Chief Scientific Officer receives 25,000 stock options grant - Stock Titan
Medicus Pharma (MDCX) grants CFO 100,000 stock options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) CEO awarded 325,000 options at $0.50 strike - Stock Titan
Medicus Pharma (NASDAQ: MDCX) director receives grant of 25,000 options at $0.50 strike - Stock Titan
Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data - Yahoo! Finance Canada
Medicus Pharma Ltd clarifies positive Skinject phase 2 dataset - marketscreener.com
Medicus Pharma Ltd Clarifies Positive Skinject Phase 2 Dataset - TradingView
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset - The Manila Times
Medicus Pharma clarifies Phase 2 skin cancer study results - Investing.com
Skin cancer study points to stronger results at higher SkinJect dose - Stock Titan
MDCXW Financials: Income Statement, Balance Sheet & Cash Flow | Medicus Pharma Ltd - Stock Titan
MDCX Stock Price, Quote & Chart | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Ideas Watch: Is Medicus Pharma Ltd Equity Warrant likely to announce a buybackQuarterly Portfolio Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Small cap wrap: Namibia Critical Metals, Medicus Pharma, Greatland Resources... - Proactive financial news
Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate - TipRanks
Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2 - TipRanks
D. Boral Capital cuts Medicus Pharma stock price target on dilution concerns - ca.investing.com
Medicus Pharma highlights independent support for Phase 2 SkinJect results - Yahoo Finance
Medicus Pharma Ltd Reports KOL Validation of Skinject Phase 2 Data of 80% Overall Response Rate - MarketScreener
Medicus Pharma reports Kol validation of Skinject phase 2 data of 80% overall response rate - MarketScreener
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate - Caledonian Record
[EFFECT] Medicus Pharma Ltd. SEC Filing - Stock Titan
Bull Bear: Is Medicus Pharma Ltd Equity Warrant stock forming a cup and handleMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
Free cash flow per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Medicus Pharma (MDCX): A Small-Cap Biotech Making Moves in 2026 - openPR.com
Medicus Pharma reports 80% response rate in skin cancer study By Investing.com - Investing.com South Africa
Medicus Pharma to host business update call featuring clinical investigator - MSN
Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Medicus Pharma Ltd-Aktie (MDCX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| VELOCITY FUND PARTNERS, LP | 10% Owner |
May 20 '25 |
Sale |
7.72 |
75,000 |
578,940 |
3,248,741 |
1.73%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):